Stockwatch: M&A speculation in the dog days of summer
This article was originally published in Scrip
Executive Summary
The biggest merger and acquisition news of 2014 is the M&A deal that hasn't happened yet between Pfizer and AstraZeneca, but speculation about the next likely multibillion-dollar deal is moving biotechnology and pharmaceutical stock prices higher during the dog days of summer.